Infections after CAR-T therapy for blood cancers
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy, Infections clinical trials.
This study tracks infections in people who receive CAR-T cell therapy for certain blood cancers like multiple myeloma and B-cell non-Hodgkin lymphoma. It aims to understand how often infections happen and how to prevent them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have multiple myeloma or a type of B-cell non-Hodgkin lymphoma (like DLBCL, high-grade B-cell lymphoma, primary mediastinal B-cell lymphoma, follicular lymphoma, or mantle cell lymphoma).
- You must be 18 years old or older when you get CAR-T therapy.
- You must receive your CAR-T infusion at the IRCCS Azienda Ospedaliero-Universitaria di Bologna.
- You must sign a consent form agreeing to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a CAR-T cell therapy for people with certain types of blood cancer that have come back or not responded to standard treatment. The therapy targets specific markers on cancer cells to help your immune system fight the disease.
This study looks at tissue samples from adults who are receiving CAR-T cell therapy for blood-related conditions. It aims to learn more about how CAR-T works and what changes happen in the body, which may help improve future care.
This trial tests a new CAR-T cell therapy for people with certain blood cancers (B-cell acute lymphoblastic leukemia, B-cell lymphoma, or multiple myeloma) that have come back or stopped responding to treatment. The therapy uses your own immune cells, modified in a lab to attack cancer cells, then given back to you intravenously.
This study looks at how your immune system responds after you receive CAR-T cell therapy for multiple myeloma. The goal is to learn more about the treatment's effects and how well it works.
This trial tests whether CAR-T cells, a type of immunotherapy that targets specific markers on cancer cells, can treat blood cancers that have come back or not responded to standard treatment. It may offer a new option for people with lymphoma, leukemia, or multiple myeloma.
This study looks at how CAR-T therapy affects blood cell counts (cytopenia) in people with multiple myeloma or certain lymphomas/leukemias. You will provide biological samples to help researchers understand these effects.
Hear when a new Relapsed Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.